Resistin, exercise capacity, and inducible ischemia in patients with stable coronary heart disease: Data from the Heart and Soul study (Q33720243)

28 July 2017

title

Resistin, exercise capacity, and inducible ischemia in patients with stable coronary heart disease: data from the Heart and Soul study (English)

1 reference

28 July 2017

Resistin, exercise capacity, and inducible ischemia in patients with stable coronary heart disease: Data from the Heart and Soul study (English)

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.09.015

3 August 2024

main subject

coronary artery disease

1 reference

3

Nelson B Schiller

1 reference

28 July 2017

4

Mary A Whooley

1 reference

28 July 2017

Beeya Na

2

1 reference

28 July 2017

Mary H. Zhang

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20951381

3 August 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20951381

3 August 2024

publication date

24 September 2010

1 reference

full work available at URL

28 July 2017

https://api.elsevier.com/content/article/PII:S0021915010007434?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.09.015

https://api.elsevier.com/content/article/PII:S0021915010007434?httpAccept=text/plain

3 August 2024

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.09.015

3 August 2024

1 reference

28 July 2017

volume

213

1 reference

28 July 2017

issue

2

1 reference

28 July 2017

page(s)

604-610

1 reference

Resistin, obesity, and insulin resistance--the emerging role of the adipocyte as an endocrine organ

28 July 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.09.015

The hormone resistin links obesity to diabetes

3 August 2024

2

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.09.015

Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators

3 August 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.09.015

Comparative studies of resistin expression and phylogenomics in human and mouse

3 August 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.09.015

Resistin is an inflammatory marker of atherosclerosis in humans.

3 August 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.09.015

Cross-sectional associations of resistin, coronary heart disease, and insulin resistance

3 August 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.09.015

Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects

3 August 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.09.015

Resistin is associated with biomarkers of inflammation while total and high-molecular weight adiponectin are associated with biomarkers of inflammation, insulin resistance, and endothelial function

3 August 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.09.015

Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro.

3 August 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.09.015

Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction

3 August 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.09.015

The potential role of resistin in atherogenesis.

3 August 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.09.015

Resistin worsens cardiac ischaemia-reperfusion injury

3 August 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.09.015

Serum Resistin (FIZZ3) Protein Is Increased in Obese Humans

3 August 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.09.015

Correlation between serum resistin level and adiposity in obese individuals

3 August 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.09.015

Enzyme-linked immunosorbent assay for circulating human resistin: resistin concentrations in normal subjects and patients with type 2 diabetes

3 August 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.09.015

Associations between serum resistin levels and insulin resistance, inflammation, and coronary artery disease.

3 August 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.09.015

Resistin and adiponectin levels in subjects with coronary artery disease and type 2 diabetes

3 August 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.09.015

C-reactive protein and ischemia in users and nonusers of beta-blockers and statins: data from the Heart and Soul Study

3 August 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.09.015

Inducible ischemia and the risk of recurrent cardiovascular events in outpatients with stable coronary heart disease: the heart and soul study

3 August 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.09.015

ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines).

3 August 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.09.015

Exercise capacity and mortality among men referred for exercise testing

3 August 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.09.015

Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms

3 August 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.09.015

Association of plasma resistin levels with coronary heart disease in women.

3 August 2024

23

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.09.015

Serum concentrations of leptin, adiponectin and resistin, and their relationship with cardiovascular disease in patients with end-stage renal disease

3 August 2024

24

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.09.015

Increased resistin blood levels are not associated with insulin resistance in patients with renal disease

3 August 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.09.015

Ability of exercise testing to predict cardiovascular and all-cause death in asymptomatic women: a 20-year follow-up of the lipid research clinics prevalence study

3 August 2024

26

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.09.015

Prognostic usefulness of positive or negative exercise stress echocardiography for predicting coronary events in ensuing twelve months

3 August 2024

27

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.09.015

Outcomes of patients with reduced exercise capacity at time of exercise echocardiography

3 August 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.09.015

Outcome after abnormal exercise echocardiography for patients with good exercise capacity: prognostic importance of the extent and severity of exercise-related left ventricular dysfunction

3 August 2024

29

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.09.015

Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease

3 August 2024

30

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.09.015

C-reactive protein levels and outcomes after statin therapy

3 August 2024

31

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.09.015

The prognostic value of a nomogram for exercise capacity in women

3 August 2024

32

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.09.015

Nomogram based on metabolic equivalents and age for assessing aerobic exercise capacity in men.

3 August 2024

33

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.09.015

Inflammatory response in the elderly

3 August 2024

34

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.09.015

Resistin / Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans

3 August 2024

35

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.09.015

Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome

3 August 2024

36

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.09.015

Pharmacodynamic effects of rosiglitazone in nondiabetic patients with metabolic syndrome

3 August 2024

37

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.09.015

3 August 2024

Identifiers

1 reference

28 July 2017

1 reference